Freya Pharma Solutions has announced it will change its name to Arletta Pharma Solutions from 1 December 2025, signalling what the company describes as a decisive new chapter in its efforts to advance treatments for Female Sexual Disorders. The announcement was made on 27 November 2025 from Amsterdam, marking a turning point as the company moves closer to key clinical milestones for its lead therapy, Lybrido™.
The company said the new name, inspired by a rare butterfly species, reflects both scientific progress and a broader commitment to supporting women through major physiological transitions. Chief Executive Officer Nicole Hijnen said the decision captures the organisation’s transformation at a critical moment. “Like a caterpillar emerging as a butterfly, this name change marks the beginning of our company’s final phase,” she said. “This rebranding comes at the optimal moment in our evolution—as we advance our clinical programs and prepare to deliver on our founding mission to address a significant unmet medical need affecting millions of women worldwide.”
Arletta Pharma emphasised that the butterfly carries long-established symbolism within women’s medicine, citing its frequent appearance in anatomical terminology and diagnostic indicators. The company said this symbolism aligns with the experiences of women across puberty, reproductive years, perimenopause and postmenopause, all periods requiring distinct clinical understanding. Its work in Female Sexual Interest/Arousal Disorder (FSIAD) is intended to reflect these transitions, acknowledging the complexities of female sexual health.
Current clinical activity includes the ongoing Clitoral Doppler Duplex Ultrasonography Phase II study at Chaim Sheba Medical Center. The trial is assessing two testosterone-sildenafil combinations in 16 premenopausal women with acquired generalised FSIAD, using advanced imaging techniques to measure clitoral blood flow. The study is led by Prof. Cobi Reisman and Dr. Anna Padoa, with preliminary findings expected shortly. In parallel, preparations continue for the ALETTA pivotal study across 20 research sites in five European countries. The company said enrolment is expected to begin once financing arrangements are finalised, describing the study as a key step toward European regulatory approval.
Arletta Pharma’s development of Lybrido™ remains central to its portfolio. The on-demand dual-action therapy, designed for FSIAD and Hypoactive Sexual Desire Disorder, is built on fifteen years of research. Lybrido™ uses a dual-route, dual-release tablet combining a testosterone coating and a sildenafil inner core, engineered so that the peak concentration of sildenafil aligns with the testosterone-driven period of increased sexual motivation. The therapy has been studied extensively in 20 Phase I and Phase IIa trials, as well as large Phase IIb trials at 17 US sites.
